ANIMAL MODEL FOR NEPHROPATHY AND AGENTS FOR TREATING THE SAME

A non-human transgenic animal expressing ApoL1 is provided as well as a method for generating the same. Also provided is a method for identifying an agent capable of reducing the progression of an ApoL1 mediated nephropathy. Furthermore, an isolated antibody is provided which binds to the human vari...

Full description

Saved in:
Bibliographic Details
Main Authors PETERSON, ANDREW, WILSON, DEANNA GRANT, FOREMAN, ODED, WEN, XIAOHUI, SCALES, SUZANNA J
Format Patent
LanguageEnglish
French
Published 19.05.2016
Subjects
AGRICULTURE
ANIMAL HUSBANDRY
BEER
BIOCHEMISTRY
CARE OF BIRDS, FISHES, INSECTS
CHEMISTRY
COMPOSITIONS THEREOF
CULTURE MEDIA
ENZYMOLOGY
FISHING
FORESTRY
HUMAN NECESSITIES
HUNTING
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
MICROBIOLOGY
MICROORGANISMS OR ENZYMES
MUTATION OR GENETIC ENGINEERING
NEW BREEDS OF ANIMALS
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS
REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR
SPIRITS
TRAPPING
VINEGAR
WINE
Online AccessGet full text

Cover

More Information
Summary:A non-human transgenic animal expressing ApoL1 is provided as well as a method for generating the same. Also provided is a method for identifying an agent capable of reducing the progression of an ApoL1 mediated nephropathy. Furthermore, an isolated antibody is provided which binds to the human variants of ApoL1. La présente invention concerne un animal transgénique non humain exprimant ApoL1 ainsi qu'un procédé de génération de celui-ci. L'invention concerne également un procédé permettant d'identifier un agent capable de réduire la progression d'une néphropathie médiée par ApoL1. En outre, l'invention concerne un anticorps isolé qui se lie aux variants humains de ApoL1.
Bibliography:Application Number: WO2015US59987